Interventional Research Studies of Brentuximab Vedotin in R/R DLBCL

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Category

Therapeutic Area

Region

Submission Countdown

Days
Hours

Date RFP Issued: February 3, 2026

Geographic Scope: United States

Clinical Area: Oncology – Hematology – Large B Cell Lymphoma

Application Due Date: March 16, 2026

Specific Area of Interest: Projects that will be considered for Pfizer support will focus on generating evidence on priority gaps in the use of brentuximab vedotin in DLBCL aligned with our areas of interest focusing on administration of brentuximab vedotin alone or in combination with other approved agents pre and/or peri CAR-T.

PIRA™ suggested Proposal

PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.